IND Firms Contend Lax NDI Notification Enforcement Threatens Their Chances

Three pharma submit similar complaints to FDA's NAC docket stating the FDA isn’t sufficiently protecting their interests by allowing use of dietary ingredients similar to the drugs they’re developing.